Magnesium-ibogaine therapy in veterans with traumatic brain injuries
These veterans traveled abroad and paid for treatment — what happens to such effects when tested against a control group on US soil?
Suggestive but preliminary. Not settled. how we score evidence
Caveat on this rating: Treatment was delivered by Ambio Life Sciences, whose shareholders are coauthors and patent applicants; Stanford analysis was philanthropically funded and independent of the clinic. Uncontrolled design caps what this can show regardless.
No FDA efficacy trials — observational evidence only; documented cardiac (QT) risk. Texas SB 2308 (Jun 2025) funds an FDA-track trial program.
In 30 male Special Operations veterans with mostly mild TBI who self-selected into magnesium-ibogaine treatment at a Mexican clinic, disability, PTSD, depression and anxiety ratings improved markedly one month later (d≈2.1-2.8) with no serious adverse events — but with no control group, regression to the mean, expectancy and the retreat setting can explain an unknown share of the change.
Worth asking
These veterans traveled abroad and paid for treatment — what happens to such effects when tested against a control group on US soil?
Source
Magnesium-ibogaine therapy in veterans with traumatic brain injuries — Cherian KN, et al. (2024)
Reputable peer-reviewed journal
Read the source: https://doi.org/10.1038/s41591-023-02705-w
DOI: 10.1038/s41591-023-02705-w
How this was scored
- Study design
- Case series or case report
- Funding
- Independently funded
- Published in
- Reputable peer-reviewed journal
- Sample size
- 30
- Preregistered
- Yes
- Conflicts disclosed
- Yes
- Independent of proponent
- No
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "early signal". Suggestive but preliminary. Not settled. It scores 51 out of 100 on our published rubric. One caveat travels with that badge: Treatment was delivered by Ambio Life Sciences, whose shareholders are coauthors and patent applicants; Stanford analysis was philanthropically funded and independent of the clinic. Uncontrolled design caps what this can show regardless. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Magnesium-ibogaine therapy in veterans with traumatic brain injuries — Cherian KN, et al. (2024). Published in: Reputable peer-reviewed journal. DOI: 10.1038/s41591-023-02705-w. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Case series or case report. Funding: Independently funded. The researchers were not independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is ibogaine FDA approved for this use?
No. Its current status is: Preclinical research. No FDA efficacy trials — observational evidence only; documented cardiac (QT) risk. Texas SB 2308 (Jun 2025) funds an FDA-track trial program.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.